Matthew Phipps

Stock Analyst at William Blair

(0.40)

# 4,254

Out of 5,179 analysts

3

Total ratings

n/a

Success rate

-6.7%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - General

Stocks Rated by Matthew Phipps

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NCNA NuCana	Downgrades: Market Perform	n/a	$1.40	-	1	Aug 30, 2024
	AMGN Amgen	Upgrades: Outperform	n/a	$348.77	-	1	May 3, 2024
	NAMS NewAmsterdam Pharma Company	Initiates: Outperform	n/a	$29.98	-	1	Dec 19, 2022

NuCana

Aug 30, 2024

Downgrades: Market Perform

Price Target: n/a

Current: $1.40

Upside: -

Amgen

May 3, 2024

Upgrades: Outperform

Price Target: n/a

Current: $348.77

Upside: -

NewAmsterdam Pharma Company

Dec 19, 2022

Initiates: Outperform

Price Target: n/a

Current: $29.98

Upside: -